NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 12 April 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice-chair) Present for all items
3. Professor Abdallah Al-Mohammad Present for all items
4. Richard Ballerand Present for all items
5. Dr Craig Buckley Items 1 to 6.2.2
6. Dr Andrew Champion Present for all items
7. Ana Duarte Items 1 to 4.2.2
8. Dr Steve Edwards Present for all items
9. Dr Rita Faria Present for all items
10. Professor Khalida Ismail Present for all items
11. Dr Bernard Khoo Items 7 to 7.2.2
12. Dr Fiona MacPherson Smith Present for all items
13. Dr David Maudgil Items 1 to 5.2.2
14. Professor G.J. Melendez-Torres Present for all items
15. Stella O’Brien Present for all items
16. Malcolm Oswald Items 6 to 7.2.2
17. Hugo Pedder Present for all items
18. Alan Thomas Present for all items

NICE staff present

Janet Roberson, Associate Director Present for all items

Henry Edwards, Associate Director Items 7 to 7.2.2

Thomas Feist, Project Manager Items 1 to 4.2.2 & 6 to 6.2.2

Rebecca Richardson, Project Manager Items 5 to 5.2.2

Jeremy Powell, Project Manager Items 7 to 7.2.2

Mary Hughes, Heath Technology Assessment Adviser Items 1 to 4.2.2

Joanna Richardson, Heath Technology Assessment Adviser Items 5 to 5.2.2

Rufaro Kausi, Heath Technology Assessment Adviser Items 6 to 6.2.2

Michelle Green, Heath Technology Assessment Adviser Items 6 to 6.2.2

Hannah Nicholas, Heath Technology Assessment Adviser Items 7 to 7.2.2

Alexandra Sampson, Heath Technology Assessment Analyst Items 1 to 4.2.2

Lizzie Walker, Heath Technology Assessment Analyst Items 5 to 5.2.2

Sarah Wilkes, Heath Technology Assessment Analyst Items 6 to 6.2.2

Emily Leckenby, Heath Technology Assessment Analyst Items 7 to 7.2.2

Lewis Ralph, Heath Technology Assessment Analyst Present for all items

Adam Storrow, Business Analyst, RIA Present for all items

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment, Present for all items

Neha Jiandani, Technical Analyst, Commercial Liaison Items 1 to 4.2.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Items 7.1.3 to 7.2.2

Helen Barnett, Senior Medical Editor Items 1 to 4.2.2

Anna Sparshatt, Senior Medical Editor Items 5 to 6.2.2

Sarah Bromley, Senior Medical Editor Items 7 to 7.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.1.3

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 5 to 5.1.3

Catherine Pank, Assistant Project Manager, COT Items 5 to 5.2.2

Lyn Davis, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Lucinda Evans, Coordinator, MIP Items 5 to 5.1.3 & 7 to 7.2.2

Gemma Smith, Coordinator, COT Present for all items

Marcia Miller, Administrator, TA Items 1 to 4.2.2 & 6 to 6.2.2

Laura Kelly, Administrator, TA Items 5 to 5.2.2

Rumana Zaman, Administrator, TA Items 7 to 7.2.2

External assessment group representatives present

Rob Riemsma, Kleijnen Systematic Reviews Ltd (KSR Items 1 to 4.1.3

Ben Wijnen, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Willem Witlox, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Geoff Frampton, Southampton Health Technology Assessment Centre (SHTAC), Items 5 to 5.1.3

Neelam Kalita, Southampton Health Technology Assessment Centre (SHTAC), Items 5 to 5.1.3

Joanne Lord, Southampton Health Technology Assessment Centre (SHTAC), Items 5 to 5.1.3

Matt Stevenson, School of Health, and Related Research (ScHARR), Items 6 to 6.1.3

Aline Navega-Biz, School of Health, and Related Research (ScHARR), Items 6 to 6.1.3

Charlotte Kennedy, Aberdeen HTA Group Items 7 to 7.1.3

Dwayne Boyers, Aberdeen HTA Group Items 7 to 7.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, job title, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 6.2.2

Dr Shirley D’Sa, Consultant Haematologist and Honorary Associate Professor, Clinical expert nominated by WMUK, Items 1 to 4.1.3

Dr Dima El-Sharkawi, Haematology Consultant, Clinical expert nominated by Royal College of Pathologists, Items 1 to 4.1.3

Ronald Pressword, Patient expert nominated by WMUK, Items 1 to 4.1.3

Jane Nicholson, Patient expert nominated by WMUK, 1 to 4.1.3

Louise Binns, Patient expert nominated by British Association of Skin Cancer Specialist Nurses, Items 5 to 5.1.3

Dr Rakesh Patalay, Consultant Dermatologist, Clinical expert nominated by British Association of Dermatologists, Items 5 to 5.1.3

Dr Andrew Sykes, Consultant Clinical Oncologist, Clinical expert nominated by Sanofi, Items 5 to 5.1.3

Holly Heath, Patient expert nominated by Breast Cancer Now, Items 6 to 6.1.3

NICE Observers present

Karen Facey, Rare disease consultant, HST and Life Sciences Team, Items t to 4.2.2 & 7 to 7.2.2

Gary Ford, recently appointed Appeal Panel Member, NICE, Items 1 to 6.2.2

## Minutes

### Introduction to the meeting

* 1. The chair Dr Jane Adam welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 15 March 2022.

### Appraisal of zanubrutinib for treating waldenstrom's macroglobulinaemia [ID1427]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from BeiGene.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Dr Shirley D’Sa declared direct and indirect financial interests as she has received grant and advisory board fees from BeiGene and WMUK has received sponsorship from BeiGene towards the costs of the WMUK 2019 Patient / Doctor Summit. It was agreed that her declarations would not prevent Dr D’Sa from proving expert advice to the committee.
* Nominated clinical expert Dr Dima El-Sharkawi declared direct financial and non-financial interests as she has received advisory board and honoraria fees from AbbVie, AstraZeneca, Beigene, Janssen and Roche she is also a trustee of WMUK national charity. It was agreed that her declarations would not prevent Dr El-Sharkawi from proving expert advice to the committee.
* No further interests were declared for this appraisal
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Andrew Champion, Richard Ballerand and Dr Steve Edwards.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10705>

### Appraisal of cemiplimab for treating cutaneous squamous cell carcinoma - CDF review of TA592 [ID3883]

* 1. Part 1 – Open session
     1. The chair Dr Jane Adam welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Sanofi.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Dr Andrew Sykes has received honoraria of £420 from Sanofi for a lecture on cemiplimab that he gave in November 2021. It was agreed that her declarations would not prevent Dr Sykes from provding expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr David Maudgil, Hugo Pedder and Alan Thomas.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10898>

### Appraisal of pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer [ID1546]

* 1. Part 1 – Open session
     1. The chair Dr Jane Adam welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, the patient expert, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10417>

### Appraisal of Teduglutide for treating short bowel syndrome [ID3937]

* 1. Part 1 – Open session
     1. The chair Dr Jane Adam welcomed the external assessment group representatives, members of the public and company representatives from Takeda UK.
     2. The chair asked all committee members, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 - Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10842>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 10 May 2022 and will start promptly at 09.30.